AbbVie Soothes Safety Fears With More Upadacitinib RA Data

Following the fifth positive pivotal trial for AbbVie's JAK1 inhibitor in rheumatoid arthritis, it is looking increasingly likely that upadacitinib is going to be approved next year, although the company is hoping robust safety data mean that it will not get a black box warning similar to the one issued by the FDA for Lilly's recently approved same-class rival Olumiant.

Safety
Regulators may tread carefully when reviewing AbbVie's upadacitinib • Source: Shutterstock

With filings imminent for upadacitinib, AbbVie Inc. has announced positive results from a fifth late-stage trial assessing the investigational JAK1 inhibitor in rheumatoid arthritis (RA) which could help allay safety concerns regulators may have about the closely watched drug.

The US firm has presented top-line results which show that the SELECT-EARLY Phase III trial met the co-primary endpoints of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category